Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest from Andrew McConaghie
Aucatzyl will look to take market share from Gilead’s Tecartus, and the US approval is a boost for the firm and the wider UK biotech sector.
The Danish company believes amylin analog petrelintide can compete with GLP-1 agonists – and hopes an imminent Phase III readout from Novo Nordisk’s rival drug will give it a boost too.
AstraZeneca has played down the risk to its operations as its China head Leon Wang is ‘detained’ by authorities amid a number of investigations in the country.
The biotech’s challenger CAR-T is matching Carvytki in efficacy and showing an edge in safety in abstract data released ahead of the December meeting.
The UK-based company is playing catch up in obesity, but believes it has a unique offering in a three-in-one therapy now moving into Phase II.
While Eisai/Biogen and Eli Lilly are focused on knocking down barriers to uptake for their anti-amyloid drugs, Roche hopes it can beat them both on safety and efficacy with its brain shuttle technology.